(1)

The active substances 2,5-dichlorobenzoic acid methylester, acequinocyl, acetic acid, aluminium phosphide, amidosulfuron, buprofezin, calcium carbide, emamectin, ethylene, fatty acids C7 to C20, fenoxaprop-P, flonicamid (IKI-220), halosulfuron-methyl, iron sulphate, magnesium phosphide, metamitron, orange oil, quinmerac, sodium silver thiosulfate, sulcotrione, tembotrione, Trichoderma asperellum strains ICC012, T25 and TV1, Trichoderma atroviride strain T-11, Trichoderma gamsii strain ICC080, Trichoderma harzianum strains T-22 and ITEM 908, and zinc phosphide were approved as active substances for use in plant protection products for a limited period of time and the applications for the renewal of their approvals are currently being evaluated pursuant to Article 14 of Regulation (EC) No 1107/2009.

(2)

Commission Directive 2008/40/EC (2) included amidosulfuron in Annex I to Council Directive 91/414/EEC (3) as an active substance until 31 December 2018 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011 (4). The approval of amidosulfuron was extended seven times, most recently by Commission Implementing Regulation (EU) 2025/787 (5) until 30 November 2026.

(3)

Commission Directive 2008/66/EC (6) included fenoxaprop-P in Annex I to Directive 91/414/EEC as an active substance until 31 December 2018 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of fenoxaprop-P was extended nine times, most recently by Implementing Regulation (EU) 2025/787 until 30 November 2026.

(4)

Commission Directive 2008/113/EC (7) included Trichoderma asperellum strains ICC012, T25 and TV1, Trichoderma atroviride strain T-11, Trichoderma gamsii strain ICC080, and Trichoderma harzianum strains T-22 and ITEM 908 in Annex I to Directive 91/414/EEC as active substances until 30 April 2019 and they were subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approvals of all those active substances were extended six times, most recently by Commission Implementing Regulation (EU) 2025/99 (8) until 30 November 2026.

(5)

Commission Directive 2008/125/EC (9) included 2,5-dichlorobenzoic acid methylester, aluminium phosphide, magnesium phosphide, metamitron and sulcotrione in Annex I to Directive 91/414/EEC as active substances until 31 August 2019 and they were subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approvals of 2,5-dichlorobenzoic acid methylester, aluminium phosphide, magnesium phosphide, metamitron and sulcotrione were extended three times, most recently by Commission Implementing Regulation (EU) 2023/1446 (10) until 30 November 2026.

(6)

Commission Directive 2008/127/EC (11) included acetic acid, calcium carbide, ethylene, fatty acids C7 to C20 and iron sulphate in Annex I to Directive 91/414/EEC as active substances until 31 August 2019 and they were subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approvals of acetic acid, calcium carbide and ethylene were extended three times, of iron sulphate five times and of fatty acids C7 to C20 six times, most recently by Implementing Regulation (EU) 2023/1446 for acetic acid, calcium carbide ethylene and iron sulphate until 30 November 2026, and by Commission Implementing Regulation (EU) 2024/2221 (12) for fatty acids C7 to C20 until 1 December 2026.

(7)

Commission Directive 2010/29/EU (13) included flonicamid (IKI-220) in Annex I to Directive 91/414/EEC as an active substance until 31 August 2020 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of flonicamid (IKI-220) was extended two times, most recently by Implementing Regulation (EU) 2023/1446 until 30 November 2026.

(8)

Commission Directive 2010/85/EU (14) included zinc phosphide in Annex I to Directive 91/414/EEC as an active substance until 30 April 2021 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of zinc phosphide was extended three times, most recently by Commission Implementing Regulation (EU) 2024/1206 (15) until 31 December 2026.

(9)

Commission Directive 2010/89/EU (16) included quinmerac in Annex I to Directive 91/414/EEC as an active substance until 30 April 2021 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of quinmerac was extended three times, most recently by Implementing Regulation (EU) 2024/1206 until 31 December 2026.

(10)

Commission Directive 2011/6/EU (17) included buprofezin in Annex I to Directive 91/414/EEC as an active substance until 31 January 2021 and it was subsequently included in Part A of the Annex to Implementing Regulation (EU) No 540/2011. The approval of buprofezin was extended four times, most recently by Commission Implementing Regulation (EU) 2025/1489 (18) until 15 December 2026.

(11)

Commission Implementing Regulation (EU) No 356/2013 (19) approved the active substance halosulfuron-methyl until 30 September 2023 and included it in Part B of the Annex to Implementing Regulation (EU) No 540/2011. The approval of halosulfuron-methyl was extended two times, most recently by Implementing Regulation (EU) 2025/99 until 15 November 2026.

(12)

Commission Implementing Regulation (EU) No 828/2013 (20) approved the active substance emamectin until 30 April 2024 and included it in Part B of the Annex to Implementing Regulation (EU) No 540/2011. The approval of emamectin was extended two times, most recently by Implementing Regulation (EU) 2024/2221 until 15 November 2026.

(13)

Commission Implementing Regulation (EU) No 1165/2013 (21) approved the active substance orange oil until 30 April 2024 and included it in Part B of the Annex to Implementing Regulation (EU) No 540/2011. The approval of orange oil was extended two times, most recently by Implementing Regulation (EU) 2024/1206 until 31 December 2026.

(14)

Commission Implementing Regulation (EU) No 1192/2013 (22) approved the active substance tembotrione until 30 April 2024 and included it in Part B of the Annex to Implementing Regulation (EU) No 540/2011. The approval of tembotrione was extended two times, most recently by Implementing Regulation (EU) 2024/1206 until 31 December 2026.

(15)

Commission Implementing Regulation (EU) No 1195/2013 (23) approved the active substance sodium silver thiosulfate until 30 April 2024 and included it in Part B of the Annex to Implementing Regulation (EU) No 540/2011. The approval of sodium silver thiosulfate was extended two times, most recently by Implementing Regulation (EU) 2024/1206 until 31 December 2026.

(16)

Commission Implementing Regulation (EU) No 496/2014 (24) approved the active substance acequinocyl until 30 April 2024 and included it in Part B of the Annex to Implementing Regulation (EU) No 540/2011. The approval of acequinocyl was extended two times, most recently by Implementing Regulation (EU) 2024/2221 until 15 November 2026.

(17)

As the approvals of these active substances are likely to expire before decisions have been taken on their renewal as part of the ongoing renewal procedures, the Commission inquired with the rapporteur Member States concerned and the European Food Safety Authority (‘the Authority’) on the reasons for the delays in the renewal procedures of these active substances. The Commission also asked when the draft renewal assessment reports by the rapporteur Member States or the conclusions of the Authority were expected to be finalised.

(18)

The information available, including that provided by the rapporteur Member States and the Authority, shows that the reasons for the delays in each of these renewal procedures are beyond the control of the applicants.

(19)

Therefore, taking into account the temporary and exceptional nature of the mechanism for the extension of approvals, the approval periods of those active substances should be extended for the period assessed as necessary, in each specific case and on the basis of the information available at the moment of adoption of this Regulation, to finalise the respective procedures on the renewal of the approvals. Given that the case-by-case assessment of the time needed to complete each renewal procedure is based on estimates, account should be taken of this degree of uncertainty.

(20)

The applications for the renewal of the approval of the active substances 2,5-dichlorobenzoic acid methylester, acetic acid, aluminium phosphide, amidosulfuron, buprofezin, calcium carbide, ethylene, fatty acids C7 to C20, fenoxaprop-P, flonicamid (IKI-220), halosulfuron-methyl, iron sulphate, magnesium phosphide, metamitron, sulcotrione, Trichoderma asperellum strains ICC012, T25 and TV1, Trichoderma atroviride strain T-11, Trichoderma gamsii strain ICC080, and Trichoderma harzianum strains T-22 and ITEM 908 were submitted and are being evaluated in accordance with Commission Implementing Regulation (EU) No 844/2012 (25).

(21)

The application for the renewal of the approval of the active substance 2,5-dichlorobenzoic acid methylester was submitted on 31 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 26 October 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 13 February 2024, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 12 September and 11 November 2024. On 18 September 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 24 October 2025 within the deadline given. On 30 March 2026, the rapporteur Member State submitted the revised draft renewal assessment report to the Authority. The Authority estimates that it will be able to finalise its conclusion for 2,5-dichlorobenzoic acid methylester around January 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 17 months and 15 days, until 15 May 2028.

(22)

The application for the renewal of the approval of the active substance acetic acid was submitted on 30 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 29 September 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 23 April 2024, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 23 February and 24 April 2026. The Authority estimates that it will be able to finalise its conclusion for acetic acid by the end of December 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 23 months and 15 days, until 15 November 2028.

(23)

Two applications for the renewal of the approval of the active substance aluminium phosphide were submitted on 30 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 6 October 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 14 April 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority. The Authority estimates that it will be able to finalise its conclusion for aluminium phosphide by the end of December 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 26 months, until 31 January 2029.

(24)

The application for the renewal of the approval of the active substance amidosulfuron was submitted on 18 December 2015 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 20 April 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 31 October 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 5 October and 5 December 2022. On 23 May 2019, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 25 June 2019 within the deadline given. On 16 December 2019, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Commission Regulation (EU) 2018/605 (26), pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 13 June 2022 within the deadline given. On 24 July 2024, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance amidosulfuron in the Standing Committee on Plants, Animals, Food and Feed (‘Standing Committee’) on 2 October 2024. The draft renewal report and the draft implementing regulation were first discussed in the Standing Committee on 29 June 2026. As additional time is necessary for the Standing Committee to deliver its opinion and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 9 months, until 31 August 2027.

(25)

The application for the renewal of the approval of the active substance buprofezin was submitted on 29 January 2019 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 11 February 2020 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 28 April 2022, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 9 June and 8 August 2022. On 28 October 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 30 November 2022 within the deadline given. On 24 July 2023, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 10 October 2023 within the deadline given. On 1 April 2025, the Authority adopted its updated conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance buprofezin in the Standing Committee on 14 May 2025. The draft renewal report and the draft implementing regulation were first discussed in the Standing Committee on 10 December 2025. The Standing Committee voted in favour of the Commission’s proposal for non-renewal of buprofezin on 25 September 2026. As additional time is necessary for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 3 months, until 15 March 2027.

(26)

The application for the renewal of the approval of the active substance calcium carbide was submitted on 30 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 30 September 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 11 January 2024, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 23 September and 22 November 2024. On 23 April 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant replied on 26 May 2025 that it is not able to provide additional data and requested the conclusion to be based on the already available data. The Authority estimates that it will be able to finalise its conclusion for calcium carbide by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.

(27)

The application for the renewal of the approval of the active substance ethylene was submitted on 23 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 14 October 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) No 844/2012 and estimates that it will be able to submit the draft renewal assessment report to the Authority by the end of December 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 30 months, until 31 May 2029.

(28)

The entry fatty acids C7 to C20 contains three individual active substances – fatty acids C7-C18 and C18 unsaturated potassium salts, capric acid and caprylic acid. Two applications for the renewal of the approval of the active substance fatty acids C7-C18 and C18 unsaturated potassium salts were submitted on 18 and 31 August 2016, respectively, one application for the renewal of the approval of the active substance capric acid was submitted on 31 August 2016 and one application for the renewal of the approval of the active substance caprylic acid was submitted on 31 August 2016. The rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 10 October 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. The rapporteur Member State submitted the draft renewal assessment reports to the Authority, on 14 July 2021 for fatty acids C7-C18 and C18 unsaturated potassium salts and on 27 April 2021 for both capric acid and caprylic acid. The Authority conducted public consultations on reports for fatty acids C7-C18 and C18 unsaturated potassium salts between 31 March and 30 May 2023 and for capric acid and caprylic acid both between 16 March and 15 May 2023. On 26 October 2023, the Authority requested additional information for all three active substances for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 24 and 27 November 2023, respectively, for fatty acids C7-C18 and C18 unsaturated potassium salts and on 27 November 2023 for both capric acid and caprylic acid within the deadline given. On 30 June 2023, the rapporteur Member State submitted the draft renewal assessment reports to the Authority. The Authority estimates that it will be able to finalise all three conclusions for fatty acids C7 to C20 by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.

(29)

The application for the renewal of the approval of the active substance fenoxaprop-P was submitted on 15 December 2015 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 3 February 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 16 March 2018, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 22 August and 21 November 2022. On 7 December 2018, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 7 January 2019 within the deadline given. On 12 July 2019, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 11 January 2022 within the deadline given. On 30 September 2024, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance fenoxaprop-P in the Standing Committee on 4 December 2024. The draft renewal report were first discussed in the Standing Committee on 24 September 2026. As additional time is necessary for the Standing Committee to deliver its opinion and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 9 months, until 31 August 2027.

(30)

The application for the renewal of the approval of the active substance flonicamid (IKI-220) was submitted on 29 August 2017 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 7 November 2017 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 5 December 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 10 June and 9 August 2024. On 16 January 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 14 February 2025 within the deadline given. On 9 March 2026, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 to be submitted by the applicant by 9 December 2027 and the submission is pending. The rapporteur Member State estimates that it will be able to submit the draft renewal assessment report to the Authority by the end of June 2029. The Authority estimates that it will be able to finalise its conclusion for flonicamid (IKI-220) by the end of March 2029, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 34 months and 15 days, until 15 October 2029.

(31)

The application for the renewal of the approval of the active substance halosulfuron-methyl was submitted on 28 September 2020 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 10 December 2020 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 8 March 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 14 July and 12 September 2023. On 20 November 2023, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 5 January 2024 within the deadline given. On 23 May 2025, the Authority adopted its conclusion and communicated it to the applicant, the Member States and the Commission. The Commission initiated preliminary discussions on the renewal of the approval of the active substance halosulfuron-methyl in the Standing Committee on 9 July 2025. The draft renewal report were first discussed in the Standing Committee on 24 September 2026. As additional time is necessary for the Standing Committee to deliver its opinion and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 9 months, until 15 August 2027.

(32)

The application for the renewal of the approval of the active substance iron sulphate was submitted on 24 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 6 September 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) No 844/2012 and estimates that it will be able to submit the draft renewal assessment report to the Authority by the end of December 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 42 months, until 31 May 2030.

(33)

The application for the renewal of the approval of the active substance magnesium phosphide was submitted on 30 August 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 6 October 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 14 April 2023, the rapporteur Member State submitted the draft renewal assessment report to the Authority. The Authority estimates that it will be able to finalise its conclusion for magnesium phosphide by the end of December 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 26 months, until 31 January 2029.

(34)

Three applications for the renewal of the approval of the active substance metamitron were submitted on 24, 25 and 29 August 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 September, and on 10 and 11 October 2016, respectively, that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) No 844/2012 and estimates that it will be able to submit the draft renewal assessment report to the Authority by the end of February 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 32 months, until 31 July 2029.

(35)

Two applications for the renewal of the approval of the active substance sulcotrione were submitted on 27 July and 29 August 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 25 October 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 24 August 2022, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 19 February and 19 April 2024. On 5 February 2025, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 5 March 2025 within the deadline given. The Authority estimates that it will be able to finalise its conclusion for sulcotrione by the end of April 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 20 months and 15 days, until 15 August 2028.

(36)

The applications for the renewal of the approvals of the active substance for Trichoderma asperellum strains ICC012, T25 and TV1 were submitted on 27, 28 and 29 April 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 May 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 31 March 2021, the rapporteur Member State submitted the draft renewal assessment reports to the Authority, which conducted a public consultation on them between 10 June and 9 August 2021 for strain ICC012, between 15 June and 14 August 2021 for strain T25, and between 22 June and 21 August 2021 for strain TV1. On 13 June 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information for Trichoderma asperellum strains ICC012, T25 and TV1 on 12, 13 and 12 July 2022, respectively, within the deadline given. The Authority estimates that it will be able to finalise its conclusions for Trichoderma asperellum strains ICC012, T25 and TV1 by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.

(37)

The application for the renewal of the approval of the active substance Trichoderma atroviride strain T-11 was submitted on 29 April 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 May 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 31 March 2021, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on them between 11 August and 10 October 2021. On 13 June 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 13 July 2022 within the deadline given. The Authority estimates that it will be able to finalise its conclusion for Trichoderma atroviride strain T-11 by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.

(38)

The application for the renewal of the approval of the active substance Trichoderma gamsii strain ICC080 was submitted on 28 April 2016 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 May 2016 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority. On 31 March 2021, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 6 August and 5 October 2021. On 13 June 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicant submitted that information on 12 July 2022 within the deadline given. The Authority estimates that it will be able to finalise its conclusion for Trichoderma gamsii strain ICC080 by the end of October 2026, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.

(39)

The applications for the renewal of the approvals of the active substance for Trichoderma harzianum strains T-22 and ITEM 908 were submitted on 29 and 28 April 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 27 May 2016 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 31 March 2021, the rapporteur Member State submitted the draft renewal assessment reports to the Authority, which conducted a public consultation on them between 20 July and 19 September 2021 for strain T-22, and between 13 July and 11 September 2021 for strain ITEM 908. On 13 June 2022, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 11 July 2022 within the deadline given. On 3 September 2026, the Authority adopted its conclusion for Trichoderma harzianum strain T-22 and communicated it to the applicant, the Member States and the Commission. As additional time is necessary for the Standing Committee to deliver its opinion and for the Commission to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 14 months, until 31 January 2028.

(40)

For the active substances 2,5-dichlorobenzoic acid methylester, acetic acid, aluminium phosphide, ethylene, iron sulphate, magnesium phosphide, metamitron and sulcotrione, the Authority, in consultation with the Member States, may still request additional information from the applicants pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012, if it considers this necessary to assess the endocrine disrupting properties of those active substances. The extension periods proposed for those active substances do not include any additional time that might be necessary to provide and evaluate that information.

(41)

Applications for the respective renewals of the approval of the active substances acequinocyl, emamectin, orange oil, quinmerac, sodium silver thiosulfate, tembotrione and zinc phosphide were submitted and are being evaluated in accordance with Commission Implementing Regulation (EU) 2020/1740 (27).

(42)

The application for the renewal of the approval of the active substance acequinocyl was submitted on 27 May 2022 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 5 May 2023 that it had assessed the admissibility of the application pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 8 January and 8 March 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. On 19 February 2026, the rapporteur Member State submitted the draft renewal assessment report to the Authority. The Authority estimates that it will be able to finalise its conclusion for acequinocyl by the end of December 2027, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 26 months, until 15 January 2029.

(43)

The application for the renewal of the approval of the active substance emamectin was submitted on 26 November 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 9 September 2022 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 24 November 2023 and 22 January 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in December 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 30 months, until 15 May 2029.

(44)

The application for the renewal of the approval of the active substance orange oil was submitted on 22 July 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 8 July 2022 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 18 April and 17 June 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in June 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 35 months, until 30 November 2029.

(45)

Two applications for the renewal of the approval of the active substance quinmerac were initially submitted on 23 and 25 April 2018 in accordance with Implementing Regulation (EU) No 844/2012 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 7 May 2018 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. On 27 March 2021, Implementing Regulation (EU) 2020/1740 became applicable to quinmerac. A new application for its renewal of the approval was submitted in accordance with that Regulation on 27 July 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 5 October 2023 that it had assessed the admissibility pursuant to Article 8 of that Regulation, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 19 February and 19 April 2024, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in December 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 29 months, until 31 May 2029.

(46)

The application for the renewal of the approval of the active substance sodium silver thiosulfate was submitted on 30 July 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 29 April 2025 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The application has been made public by the Authority, which conducted a public consultation on it between 9 September and 8 November 2025, pursuant to Article 10 of Implementing Regulation (EU) 2020/1740. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in June 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 35 months, until 30 November 2029.

(47)

The application for the renewal of the approval of the active substance tembotrione was submitted on 26 July 2021 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 22 April 2026 that it had assessed the admissibility pursuant to Article 8 of Implementing Regulation (EU) 2020/1740, and in particular its completeness and timeliness, and concluded that it was admissible. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in October 2026. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 29 months, until 31 May 2029.

(48)

The application for the renewal of the approval of the active substance zinc phosphide was initially submitted on 25 April 2018 in accordance with Implementing Regulation (EU) No 844/2012 and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 18 May 2018 that it had assessed the admissibility of the application pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular its completeness and timeliness, and concluded that it was admissible. On 27 March 2021, Implementing Regulation (EU) 2020/1740 became applicable to zinc phosphide. A new application for its renewal of the approval was submitted in accordance with that Regulation on 28 July 2021 and the rapporteur Member State has not yet assessed the admissibility pursuant to Article 8 of that Regulation. The rapporteur Member State has not finalised the risk assessments pursuant to Article 11 of Implementing Regulation (EU) 2020/1740 and estimates that it will be able to submit the draft renewal assessment report to the Commission and the Authority in December 2027. As additional time is necessary to complete the remaining steps in the renewal procedure, the duration of the extension of the approval period should be set at 41 months, until 31 May 2030.

(49)

Implementing Regulation (EU) No 540/2011 should therefore be amended accordingly.

(50)

In order to ensure that the approvals of the active substances concerned are extended before they expire, this Regulation should enter into force on the third day following that of its publication in the Official Journal of the European Union.

(51)

In case the Commission adopts a Regulation providing that the approval of an active substance listed in the Annex to this Regulation is not renewed, the Commission should set the expiry date for the approval of this active substance at the date of entry into force of that Regulation or at the same date as it stood before the adoption of this Regulation, whichever date is later. In case the Commission adopts a Regulation providing for the renewal of the approval of an active substance referred to in the Annex to this Regulation, the Commission should set, as appropriate under the circumstances, the earliest possible application date.

(52)

The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,